Unmet Medical Need
The Critical Need for Neuroprotection After Cardiac Arrest and Severe Traumatic Brain Injury (sTBI)
Every year, hundreds of thousands of individuals suffer from out-of-hospital cardiac arrest (OHCA) and severe traumatic brain injury (sTBI) with critically low survival rates. Despite successful resuscitation and intervention, survivors often face devastating outcomes:
- Post-Cardiac Arrest Syndrome (PCAS): Up to 50% of patients who survive the initial arrest die in the ICU, primarily due to severe brain injury caused by the complex cascade of reperfusion.
- Severe TBI (sTBI): similar to PCAS, survival rates in sTBI are dismal. In addition, survivors of sTBI frequently endure lifelong cognitive, physical, and behavioral disabilities.
Survival after cardiac arrest is only the beginning. When circulation is restored, the brain undergoes a rapid and destructive cascade of secondary injury — global ischemia, excitotoxicity, mitochondrial failure, inflammation, and delayed neuronal death. Current treatment is limited to supportive measures such as targeted temperature management, leaving patients at high risk of neurological impairment or death.
Severe traumatic brain injury (TBI) triggers a similar secondary injury cascade — excitotoxicity, inflammation, impaired cerebral blood flow, and progressive neuronal loss. Again, clinicians rely solely on supportive care while patients often face poor survival rates, lifelong cognitive, emotional, and functional impairments.
Despite the critical need and urgent demand along with decades of research, no commercially available neuroprotective pharmacotherapies exist for these patients, leaving clinicians with few options beyond supportive care. Therefore, a safe, rapidly deployable, mechanistically broad neuroprotectant capable of interrupting early secondary injury in real‑world emergency and critical care environments is urgently needed for both conditions.
Why Neuroprotectants Failed despite decades of research
The history of neuroprotectant development is marked by numerous failures
Historic agents failed for predictable reasons:
- Single‑pathway mechanisms that couldn’t address multi‑factorial injury
- Poor blood brain barrier penetration or slow onset
- Severe side effects including hemodynamic instability, systemic & neuro toxicities, neuropsychiatric effects, etc.
- Extremely narrow therapeutic windows
- Failure to translate from rodent models to large‑animal or human physiology
A successful neuroprotectant must be multi‑modal, rapidly acting, safe, and clinically practical.
